News

George Cox, president of Bolder BioTechnology, said: “We are grateful to receive continued support from the National Institute of Neurological Disorders and Stroke (NINDS) for our long-acting beta

The first patent covers a method for determining matching patterns within gene expression data stored in a database comprising of biological data. This methodology helps in retrieving clinically

RTA 402 is currently being studied in a Phase I/II trial in patients with pancreatic cancer, and is also in Phase II development for chronic kidney disease. Warren

This initial safety study will involve single injections of Protectan CBLB502 in ascending dose groups of six healthy volunteers each. Participants in the study will be assessed for

Amerinet partners with more than 27,000 healthcare providers nationwide to reduce costs and improve quality. This agreement makes BK Medical’s surgical ultrasound systems, related accessories, and supplies available

The Phase I intravenous (IV) trial involves treatment of patients with advanced, metastatic solid tumors refractory to standard therapy. Patients receive treatment at one of five dose levels

Syringes from Catalent’s Brussels facility will likely be dispensed to patients in the US in upcoming months. Richard Yarwood, group president of Catalent’s sterile technologies segment, said: “We

The second AZ-004 Phase III clinical trial was initiated in July 2008 with a target enrollment of 300 patients, 314 patients were enrolled and Alexza expects to announce

The study will be conducted at the Winnipeg Clinic under the guidance of principal investigator, urologist, Patrick Cho. Samples collected from the study will be tested using recently